The global, regional, and national testicular cancer burden and trends from 1990 to 2019: results from the Global Burden of Disease Study 2019

Author:

Huang Guoxin1,Li Han2,Chen Xiali1,Liu Ying1,Jiang Chenglu2,Zhang Shengke2,Pei Bin1,Sun Zhou3

Affiliation:

1. Hubei University of Medicine

2. Southwest Medical University

3. China-Japan Union Hospital, Jilin University

Abstract

Abstract Background:To assess the disease burden of Testicular Cancer (TC) from 1990 to 2019. Methods:Global, regional and national age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), age-standardized death rate (ASDR) and age-standardized disability-adjusted life years rate (DALYs) from 1990-2019 were used to analyze the disease burden of TC, combined with decomposition analyses and frontier analyses. Results: The global ADIR, ASPR, ASDR, and age-standardized DALYs in 2019 were 2.79 (2.36,3.33), 21.24 (17.59,25.94), 0.28 (0.26,0.31), and 14.24 (12.91,15.98), respectively. The burden of disease varied by region and country, with Central Europe and Southern Latin America having higher than expected levels. Chile, Tonga, and Monaco were among the countries with a higher disease burden. Decomposition analysis showed population growth as the main factor for changing age-standardized DALYs. Frontier analysis showed that age-standardized DALYs in different countries have much room for improvement, especially in Tonga and Kiribati. The global ADIR, ASPR, ASDR, and age-standardized DALYs are projected to be 3.13, 24.08, 0.29, and 15.01 by 2030. Conclusions: TC remains a global public problem. There are significant regional and national differences, and therefore different regions and countries should be targeted to improve the disease burden of TC.

Publisher

Research Square Platform LLC

Reference35 articles.

1. The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges;Mohanty SK;HUM PATHOL,2023

2. Germ cell neoplasms of the testis: Update for 2022;Iczkowski KA;SEMIN DIAGN PATHOL,2023

3. Testicular Cancer: Diagnosis and Treatment;Baird DC;AM FAM PHYSICIAN,2018

4. Testicular cancer update;Adra N;Clin Adv Hematol Oncol,2017

5. Time trends in accuracy of classification of testicular tumours, with clinical and epidemiological implications;Stone JM;Br J Cancer,1992

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3